U.S. License Holder:
Eli Lilly and Co.
Date of License:
TRULICITY (dulaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated:
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus;
To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.